- Home
- LXEH vs LPCN Comparison
LXEH vs LPCN Comparison
Compare LXEH & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- LPCN
- Stock Information
- Founded
- LXEH 2001
- LPCN 1997
- Country
- LXEH China
- LPCN United States
- Employees
- LXEH N/A
- LPCN N/A
- Industry
- LXEH Other Consumer Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- LPCN Health Care
- Exchange
- LXEH Nasdaq
- LPCN Nasdaq
- Market Cap
- LXEH 12.5M
- LPCN 13.8M
- IPO Year
- LXEH 2020
- LPCN N/A
- Fundamental
- Price
- LXEH $0.36
- LPCN $3.36
- Analyst Decision
- LXEH
- LPCN Strong Buy
- Analyst Count
- LXEH 0
- LPCN 1
- Target Price
- LXEH N/A
- LPCN $7.00
- AVG Volume (30 Days)
- LXEH 1.6M
- LPCN 55.2K
- Earning Date
- LXEH 12-30-2025
- LPCN 11-06-2025
- Dividend Yield
- LXEH N/A
- LPCN N/A
- EPS Growth
- LXEH N/A
- LPCN N/A
- EPS
- LXEH N/A
- LPCN N/A
- Revenue
- LXEH $4,585,942.00
- LPCN $4,322,693.00
- Revenue This Year
- LXEH N/A
- LPCN N/A
- Revenue Next Year
- LXEH N/A
- LPCN N/A
- P/E Ratio
- LXEH N/A
- LPCN N/A
- Revenue Growth
- LXEH N/A
- LPCN N/A
- 52 Week Low
- LXEH $0.31
- LPCN $2.52
- 52 Week High
- LXEH $50.08
- LPCN $5.50
- Technical
- Relative Strength Index (RSI)
- LXEH 29.55
- LPCN 69.63
- Support Level
- LXEH $0.35
- LPCN $2.80
- Resistance Level
- LXEH $0.40
- LPCN $3.07
- Average True Range (ATR)
- LXEH 0.05
- LPCN 0.19
- MACD
- LXEH 0.06
- LPCN 0.07
- Stochastic Oscillator
- LXEH 7.82
- LPCN 81.31
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.